Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design Academic Article Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Hypothyroidism
  • Indoles
  • Kidney Neoplasms
  • Pyrroles

abstract

  • Our findings suggest that, as a result of synergy, the doses of these agents needed to achieve an antitumor effect may be reduced by twofold to eightfold when these agents are given in combination. The present quantitative data analyses for synergism or antagonism provide a basis for a rational design of clinical protocols for combination chemotherapy in patients with advanced germ cell tumors.

publication date

  • October 19, 1994

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1093/jnci/86.20.1517

PubMed ID

  • 7932806

Additional Document Info

start page

  • 1517

end page

  • 24

volume

  • 86

number

  • 20